Stockscreener 앱 받기
186.44
3.28%
5.725
전일 마감가:
$180.71
열려 있는:
$180.72
하루 거래량:
439.29K
Relative Volume:
0.39
시가총액:
$10.52B
수익:
$763.34M
순이익/손실:
$51.40M
주가수익비율:
205.23
EPS:
0.9084
순현금흐름:
$104.46M
1주 성능:
+6.81%
1개월 성능:
+3.04%
6개월 성능:
+63.88%
1년 성능:
+48.19%
1일 변동 폭
$180.00
$188.20
1주일 범위
$171.66
$188.20
52주 변동 폭
$100.99
$188.73
Repligen Corp Stock (RGEN) Company Profile
명칭
Repligen Corp
전화
(781) 449-9560
주소
41 SEYON STREET, WALTHAM, MA
Compare RGEN vs ISRG, BDX, RMD, ALC, MDLN
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
RGEN
Repligen Corp
|
186.38 | 9.32B | 763.34M | 51.40M | 104.46M | 0.9084 |
ISRG
Intuitive Surgical Inc
|
401.99 | 130.41B | 11.03B | 3.16B | 3.22B | 8.7251 |
BDX
Becton Dickinson Co
|
181.81 | 48.44B | 21.37B | 1.41B | 3.07B | 3.9437 |
RMD
Resmed Inc
|
224.68 | 31.49B | 5.54B | 1.52B | 1.74B | 10.37 |
ALC
Alcon Inc
|
65.50 | 31.92B | 10.63B | 819.00M | 1.59B | 1.6577 |
MDLN
Medline Inc
|
33.64 | 28.54B | 29.14B | 1.07B | 1.05B | 1.1956 |
Repligen Corp Stock (RGEN) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-09-09 | 재개 | UBS | Buy |
| 2026-07-07 | 업그레이드 | The Benchmark Company | Hold → Buy |
| 2026-06-02 | 재개 | Wolfe Research | Outperform |
| 2026-05-15 | 재개 | RBC Capital Mkts | Outperform |
| 2026-04-17 | 개시 | Rothschild & Co Redburn | Buy |
| 2025-10-01 | 개시 | HSBC Securities | Buy |
| 2025-09-22 | 업그레이드 | Evercore ISI | In-line → Outperform |
| 2025-07-22 | 재개 | Stephens | Overweight |
| 2025-06-24 | 개시 | Barclays | Overweight |
| 2025-04-29 | 업그레이드 | Wolfe Research | Peer Perform → Outperform |
| 2025-03-18 | 개시 | Evercore ISI | In-line |
| 2025-02-10 | 개시 | TD Cowen | Buy |
| 2024-12-17 | 개시 | Canaccord Genuity | Hold |
| 2024-11-14 | 개시 | Wolfe Research | Peer Perform |
| 2024-08-28 | 개시 | Wells Fargo | Overweight |
| 2024-06-26 | 업그레이드 | Deutsche Bank | Hold → Buy |
| 2024-06-18 | 개시 | Guggenheim | Neutral |
| 2023-12-04 | 다운그레이드 | The Benchmark Company | Buy → Hold |
| 2023-07-20 | 개시 | Wells Fargo | Overweight |
| 2023-07-05 | 재개 | JP Morgan | Overweight |
| 2023-03-28 | 개시 | The Benchmark Company | Buy |
| 2022-12-14 | 개시 | Deutsche Bank | Hold |
| 2022-12-07 | 개시 | RBC Capital Mkts | Sector Perform |
| 2022-07-20 | 개시 | UBS | Buy |
| 2021-10-14 | 개시 | Exane BNP Paribas | Outperform |
| 2020-11-10 | 개시 | KeyBanc Capital Markets | Overweight |
| 2020-08-24 | 재확인 | H.C. Wainwright | Buy |
| 2020-06-30 | 재확인 | H.C. Wainwright | Buy |
| 2020-05-07 | 재확인 | H.C. Wainwright | Buy |
| 2020-03-23 | 재확인 | H.C. Wainwright | Buy |
| 2019-11-15 | 개시 | Stifel | Buy |
| 2019-11-01 | 업그레이드 | First Analysis Sec | Outperform → Strong Buy |
| 2019-10-15 | 개시 | SVB Leerink | Outperform |
| 2019-08-28 | 재확인 | First Analysis Sec | Outperform |
| 2019-08-23 | 재개 | Stephens | Overweight |
| 2019-07-22 | 업그레이드 | H.C. Wainwright | Neutral → Buy |
| 2018-12-17 | 업그레이드 | CL King | Neutral → Buy |
| 2018-11-12 | 다운그레이드 | CL King | Buy → Neutral |
| 2018-09-26 | 개시 | H.C. Wainwright | Neutral |
| 2017-12-08 | 개시 | Citigroup | Buy |
| 2017-12-05 | 개시 | JP Morgan | Overweight |
| 2017-11-13 | 개시 | CL King | Buy |
| 2017-10-02 | 업그레이드 | First Analysis Sec | Equal-Weight → Overweight |
| 2017-07-21 | 개시 | William Blair | Outperform |
| 2017-02-13 | 업그레이드 | Piper Jaffray | Neutral → Overweight |
모두보기
Repligen Corp 주식(RGEN)의 최신 뉴스
Could Pricing Pressure Change the Repligen (NASDAQ:RGEN) Story? - Kalkine Media
BioLife Solutions' HSR Antitrust Waiting Period Ends Ahead of Repligen Merger - Kalkine Media
REPLIGEN CEO Loeillot Olivier Forfeits 2,842 Shares at $169.61 and Sells 3,035 Shares at $165.90 (NASDAQ: RGEN) - Kalkine Media
Repligen to acquire BioLife for $11.25 cash plus 0.1442 shares per BioLife share; HSR waiting period expired - TradingView
[425] REPLIGEN CORP Business Combination Communication | RGEN SEC FilingForm 425 - Stock Titan
Repligen (RGEN) CEO trades stock in preset plan - Stock Titan
Repligen (NASDAQ: RGEN) Schedules October 5 Vote for BioLife Merger Approval - Kalkine Media
REPLIGEN CORP SEC Filing (Sep 8, 2026) - Stock Titan
ZimVie Inc. When-Issued (ZIMVV) Peer Comparison – Compare with Others - valueresearchonline.com
Repligen Stock Price Forecast. Should You Buy RGEN? - StockInvest.us
Repligen Corp (NASDAQ:RGEN) Combines Strong Growth with a Constructive Technical Setup - ChartMill
Repligen Corporation (RGEN) Shareholding Pattern – Promoters, FIIs & DIIs - valueresearchonline.com
Repligen (RGEN) holder lines up new sale after $976K trade - Stock Titan
Heska Corporation (HSKA) Peer Comparison – Compare with Others - Value Research
What Repligen (NASDAQ: RGEN) plans to pay for each BioLife share - Stock Titan
Repligen (RGEN) Stock Looks Near Fair Value After Recent Rebound - Yahoo Finance
Repligen Offers Differentiated Solutions as a Leading Bioprocessing Supplier - Morningstar
Codex DNA Inc (DNAY) Peer Comparison – Compare with Others - Value Research
Repligen (NASDAQ: RGEN) awards 2,466 stock units to its chief accounting officer - Stock Titan
A Look at Repligen Corp (RGEN) After 6.1% Decline -- GF Value $1 - GuruFocus
Acutus Medical Inc (AFIB) Peer Comparison – Compare with Others - valueresearchonline.com
Repligen Corporation (RGEN) Stock Price, Chart, News & Analysis - securities.io
Repligen Corporation (RGEN) Peer Comparison – Compare with Others - Value Research
Repligen Corp (RGEN) Shares Fall 3.2% -- What GF Score of 87 Tel - GuruFocus
Zacks Industry Outlook Halozyme, Repligen, Iovance, Arcutis and Precigen - Yahoo Finance
Repligen’s CEO and CFO join Wells Fargo conference Sept. 9 - Stock Titan
Repligen Corp (RGEN) CEO Olivier Loeillot Sells 5,426 Shares - GuruFocus
Repligen (NASDAQ: RGEN) CEO trades shares at $180 under 10b5-1 plan - Stock Titan
LVIP Baron Growth Opportunities Fund's Repligen Corp(RGEN) Holding History - GuruFocus
Repligen rises as investors continue to digest raised 2026 guidance and the BioLife deal - Quiver Quantitative
Repligen (NASDAQ: RGEN) plan covers 5,426-share sale after option exercise - Stock Titan
Repligen Corporation stock hits 52-week high at 176.52 USD By Investing.com - Investing.com South Africa
Repligen Corporation stock hits 52-week high at 176.52 USD - Investing.com
Unpacking Q2 Earnings: Repligen (NASDAQ:RGEN) In The Context Of Other Drug Development Inputs & Services Stocks - Yahoo Finance
Oppenheimer Asset Management Inc. Purchases New Position in Repligen Corporation $RGEN - MarketBeat
Repligen Corp (RGEN) stake at 3.1% in new T. Rowe Price 13G/A - Stock Titan
Repligen Corporation (RGEN) Stock Forecasts - Yahoo! Finance Canada
Wasatch Advisors LP Buys 346,720 Shares of Repligen Corporation $RGEN - MarketBeat
Assenagon Asset Management S.A. Buys New Shares in Repligen Corporation $RGEN - MarketBeat
Repligen Corporation (RGEN) stock price, news, quote and history - Yahoo Finance UK
Repligen Corporation (NASDAQ:RGEN) Given Average Rating of "Moderate Buy" by Brokerages - MarketBeat
Repligen (RGEN) Is Up 16.2% After Revenue Rises But Profitability Compresses In Q2 2026 - Yahoo Finance
Repligen Corp (RGEN) Stock News Today - TradingKey
Repligen Corp (RGEN) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
The Manufacturers Life Insurance Company Decreases Holdings in Repligen Corporation $RGEN - MarketBeat
Is It Too Late to Buy Repligen Corp (RGEN) After 5.8% Rally? GF Value Says Undervalued - GuruFocus
Moody National Bank Trust Division Makes New Investment in Repligen Corporation $RGEN - MarketBeat
California State Teachers Retirement System Raises Holdings in Repligen Corporation $RGEN - MarketBeat
Repligen Submits Form 425 Detailing Proposed Acquisition of BioLife Solutions - Kalkine Media
Repligen Corp (RGEN) Stock Up 4.3% and Still Undervalued -- GF S - GuruFocus
Repligen Earnings: Excellent Profit Margins, China Recovery Underway - Morningstar
Repligen Corp (RGEN) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Repligen Corp 주식 (RGEN) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Loeillot Olivier | Chief Executive Officer |
Sep 04 '26 |
Sale |
165.90 |
3,035 |
503,506 |
48,369 |
3.08%
자본화:
|
볼륨(24시간):